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Abstract
This article is part of a series of papers examining ethical issues in cluster randomized trials (CRTs) in health
research. In the introductory paper in this series, we set out six areas of inquiry that must be addressed if the
cluster trial is to be set on a firm ethical foundation. This paper addresses the second of the questions posed,
namely, from whom, when, and how must informed consent be obtained in CRTs in health research? The ethical
principle of respect for persons implies that researchers are generally obligated to obtain the informed consent of
research subjects. Aspects of CRT design, including cluster randomization, cluster level interventions, and cluster
size, present challenges to obtaining informed consent. Here we address five questions related to consent and
CRTs: How can a study proceed if informed consent is not possible? Is consent to randomization always required?
What information must be disclosed to potential subjects if their cluster has already been randomized? Is passive
consent a valid substitute for informed consent? Do health professionals have a moral obligation to participate as
subjects in CRTs designed to improve professional practice?
We set out a framework based on the moral foundations of informed consent and international regulatory
provisions to address each of these questions. First, when informed consent is not possible, a study may proceed if
a research ethics committee is satisfied that conditions for a waiver of consent are satisfied. Second, informed
consent to randomization may not be required if it is not possible to approach subjects at the time of
randomization. Third, when potential subjects are approached after cluster randomization, they must be provided
with a detailed description of the interventions in the trial arm to which their cluster has been randomized;
detailed information on interventions in other trial arms need not be provided. Fourth, while passive consent may
serve a variety of practical ends, it is not a substitute for valid informed consent. Fifth, while health professionals
may have a moral obligation to participate as subjects in research, this does not diminish the necessity of informed
consent to study participation.
Introduction
This article is part of a series of papers examining ethi-
cal issues in cluster randomized trials (CRTs) in health
research. CRTs are used increasingly in knowledge
translation research, quality improvement research,
community based intervention studies, public health
research, and research in developing countries. While a
small and growing literature explores ethical aspects of
CRTs, cluster trials raise difficult issues that have not
been addressed adequately. In the introductory paper in
this series, we set out six areas of inquiry that must be
addressed if the cluster trial is to be set on a firm ethical
foundation [1]. These include identifying research sub-
jects, obtaining informed consent, the applicability of
clinical equipoise, benefit-harm analysis, the protection
of vulnerable populations, and the role and authority of
gatekeepers in CRTs. This paper addresses the second
of the questions posed, namely, from whom, when, and
how must informed consent be obtained in CRTs in
health research?
Informed consent is the subject of discussion in the
CRT literature. Edwards and colleagues describe the dif-
ficulties associated with obtaining informed consent in
CRTs [2]. They distinguish between individual-cluster
trials and cluster-cluster trials, and argue that the poten-
tial to obtain informed consent is linked to the “level” at
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which study interventions are administered. In indivi-
dual-cluster trials, study interventions – such as a
patient-centered educational brochure or vaccination –
are directed at individual cluster members. These inter-
ventions could be studied in an individually randomized
trial, but a CRT may be performed due to countervailing
considerations of treatment contamination, a desire to
study group effects, logistical demands, or other practi-
cal reasons [3]. Since the “individuals within clusters are
given treatments, they can in theory consent individually
to the treatment(s) offered within their cluster” [2].
Thus, generally, informed consent should be obtained in
individual-cluster trials.
Cluster-cluster trials, on the other hand, evaluate
experimental interventions – such as mass education or
a training program for health care providers – that are
applied to entire clusters [2]. In these studies, it may
not be possible to obtain informed consent from indivi-
dual cluster members. Since the study intervention is
delivered at the cluster level, it may be very difficult for
cluster members to avoid the intervention if they don’t
wish to participate in the CRT. In these cases, “indivi-
duals cannot act independently” and “the autonomy
principle is lost” [2]. Further, when dealing with large
clusters, it may be logistically difficult to obtain
informed consent from all cluster members [2]. Thus, in
cluster-cluster trials it may not be meaningful or feasible
to obtain informed consent.
The United Kingdom Medical Research Council Clus-
ter Randomised Trials: Methodological and Ethical Con-
siderations ("MRC guidelines”) provides important
guidance to researchers and research ethics committees
on informed consent and other aspects of CRTs [4].
Broadly, the MRC guidelines follow the conclusions of
Edwards and colleagues regarding informed consent.
Individual level interventions generally “do allow indivi-
dual choice” while cluster level interventions “do not
allow individual choice” [4]. An important innovation of
the document is the recognition that a single trial may
contain both individual and cluster level interventions.
Based on this insight, the authors conclude that
informed consent should be sought where possible:
“The fact that individual choice does not exist for a
[cluster level] intervention (or for cluster randomiza-
tion) does not, for instance, prevent individual con-
sent being sought for giving a complementary
[individual level] intervention which is part of the
intervention package, or for taking samples, record-
ing information, or extracting data from records” [4].
They also suggest that when informed consent cannot
be obtained for all aspects of the study, agreement to
enroll a cluster in the study must be sought from a
gatekeeper or “cluster representation mechanism” – a
person or body charged with making decisions on behalf
of the entire cluster [4]. (The role and authority of gate-
keepers in CRTs is the subject of another paper in this
series).
These conclusions regarding the role of informed con-
sent in CRTs seem – for the most part – intuitively cor-
rect. Moreover, they are reflected in practice:
investigators routinely obtain informed consent in CRTs
evaluating individual level interventions, and they often
do not obtain informed consent in CRTs evaluating
cluster level interventions [5,6]. Nonetheless, we believe
that further work is required, since some ethical ques-
tions posed in the literature have resisted a conclusive
resolution, and the literature on CRTs remains some-
what disconnected from that on research ethics. For
conclusions regarding informed consent and CRTs to be
deemed broadly convincing by researchers, research
ethics committees, regulators, and funding agencies,
they must be based explicitly on ethical principles and
research regulations.
This paper seeks to answer the question of from
whom, when, and how must informed consent be
obtained in CRTs in health research? After reviewing
the implications of prior work in this series of articles
for informed consent, we present a conceptual founda-
tion for informed consent based on ethical theory and
the moral purpose of consent. We use this conceptual
foundation and national and international regulatory
provisions to address key questions related to informed
consent in CRTs. First, how can a study proceed if
informed consent is not possible? Second, is consent to
randomization always required? Third, what information
must be disclosed to potential subjects if their cluster
has already been randomized? Fourth, is passive consent
a valid substitute for informed consent? Fifth, do health
professionals have a moral obligation to participate as
subjects in CRTs designed to improve professional
practice?
Prior work
Prior work in this series of articles has implications for
informed consent in CRTs in health research. In a pre-
vious paper we developed a novel definition of human
research subject [7]. We argued that a human research
subject is an individual whose interests may be compro-
mised as a result of interventions in a research study
[7]. This includes any person who is directly intervened
upon by an investigator, who is deliberately intervened
upon via manipulation of the environment, with whom
an investigator interacts for the purpose of collecting
data, or about whom an investigator obtains identifiable
private information [7]. As a general rule, informed con-
sent for study participation must be obtained from
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research subjects or their surrogate decision makers.
There is no ethical or regulatory obligation to obtain
informed consent (for research purposes) from people
who do not meet the definition of human research
subjects.
This understanding of human research subject has
clear implications for informed consent in CRTs in
health research. Consider a CRT conducted by Althabe
and colleagues (the “Guidelines Trial”) that used a beha-
vioral intervention directed at health care providers to
improve obstetrical care in Argentina and Uruguay [8].
The Guidelines Trial sought to develop and implement
clinical guidelines for the use of episiotomy and the
management of the third stage of labor. The primary
outcome measures were the rates of episiotomy and
prophylactic use of oxytocin in the third stage of labor.
In total, 10 hospitals were randomized to the behavioral
intervention, while 9 hospitals were randomized to
receive no intervention. At each of the intervention hos-
pitals, teams of 3 to 6 birth attendants (physicians, resi-
dents, and midwives) were identified as opinion leaders
and they participated in a workshop to develop and dis-
seminate clinical guidelines on the outcomes of interest.
The teams then returned to their respective hospitals,
disseminated guidelines, trained the other birth atten-
dants, and implemented a system of reminders. Data on
births were collected using a standard clinical record
form, and no information identifying individual patients
was transmitted from the hospitals. Outcome measures
were collected at baseline, at the end of the 18 month
intervention period, and 12 months thereafter. The
study was approved by research ethics committees in
Argentina, Uruguay, and the United States. Informed
consent was obtained from all birth attendants in the
intervention arm, and a waiver of consent for the
patients in the study was obtained. The Guidelines Trial
intervention resulted in a 68% absolute increase in the
use of prophylactic oxytocin and an 11% absolute reduc-
tion in the use of episiotomy. These results remained
stable 12 months after the end of the intervention
period.
Who are the human research subjects in the Guidelines
Trial and from whom is informed consent required? The
birth attendants in hospitals allocated to the intervention
arm of the study were directly intervened upon through
training sessions and reminders, and accordingly they are
human research subjects. Birth attendants in hospitals
allocated to the control arm of the study were not inter-
vened upon and hence they are not research subjects.
Provided that it was feasible to do so, informed consent
ought to have been obtained from birth attendants in the
intervention arm of the study (indeed, their informed
consent was obtained). Knowledge translation trials com-
monly intervene on health professionals to change their
practice behaviours. An important implication of our
prior work is that, in these cases, health providers are
research subjects and there is a presumption that their
informed consent is required [7].
The patients in the Guidelines Trial (whether in the
intervention or the control arm) were not in a position
whereby their interests could plausibly be compromised
in the context of a research study and, accordingly, they
were not human research subjects. The study interven-
tion sought to bring the behaviour of birth attendants
with regard to the use of episiotomy and the manage-
ment of the third stage of labour in line with the best
available medical evidence. (Of course, it was not known
at the beginning of the study whether the study inter-
vention would be effective in doing so.) Importantly, the
fiduciary relationship between birth attendants and
patients remained intact and, as a result, birth atten-
dants were unimpeded in their ability to make medical
decisions in the best interests of their patients. With
regard to the specific criteria listed above, patients in
the Guidelines Trial were not directly intervened upon
by an investigator, they were not deliberately intervened
upon via manipulation of their environment, and inves-
tigators did not interact with them for the purpose of
collecting data. Data were collected on standard clinical
forms and no identifying information on patients was
transmitted beyond the hospital. Since the patients in
the Guidelines Trial were not human research subjects,
there was no obligation to obtain their informed con-
sent. As a result, it was unnecessary to secure a waiver
of consent for the study. Thus, another important impli-
cation of our prior work is that patients in knowledge
translation trials who are merely indirectly impacted by
study interventions are not human research subjects,
and their informed consent is not required.
A moral foundation of informed consent
In the introductory paper of the series, we set out a
standard framework of research ethics with four ethical
principles: respect for persons, beneficence, justice, and
respect for communities [1]. Informed consent require-
ments for research participation stem from the principle
of respect for persons, which requires that the wishes of
autonomous individuals be respected, and that indivi-
duals with diminished autonomy be protected. Autono-
mous individuals are those who are capable of self-
government and who can make responsible choices for
themselves. Autonomous choices are decisions that are
intentional, informed, and free of coercive influences [9].
The ethical principle of respect for persons may be
viewed as deriving from deontological moral theory,
which defines right action as the satisfaction of moral
duties [10]. Kantian deontological theory posits that
people have intrinsic moral worth by virtue of their
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capacity for rational decision making about their ends.
Respect for the worth of others entails a moral duty to
respect their autonomous choices. In other words,
respecting the intrinsic moral worth of people requires
that we treat them as ends in themselves, rather than as
mere means to an end [10].
Informed consent may be viewed as a Kantian duty.
Freedman explains informed consent as arising
“from the right which each of us possesses to be
treated as a person, and in the duty which all of us
have, to have respect for persons, to treat a person
as such, and not as an object. For this entails that
our capacities for personhood ought to be recog-
nized by all – these capacities including the capacity
for rational decision and for action consequent upon
rational decision” [11].
Here Freedman distinguishes how we may treat an
object from how we may treat a person. An object – be
it a tennis ball or a computer keyboard – does not have
intrinsic moral worth; its worth is merely a function of
its utility. Thus, objects are rightly used as mere means
to our own ends, whether those ends be playing tennis
or writing a paper. Freedman’s point is that people may
not be treated in this way. Each of us has a duty to
“recognize the capacities for personhood” in others and
demonstrate respect for it [11]. People are only legiti-
mately involved in my project – be it playing a game of
tennis or coauthoring a paper – when they agree to do
so as a result of a rational decision. By providing
informed consent, they in effect adopt my end as their
own. In this way, I treat them not as mere means to an
end, but as an end in themselves.
The central moral challenge of human subjects
research is what legitimates putting a person at risk pri-
marily or solely for the benefit of others. The purpose of
human subjects research is the production of knowledge
that will benefit others, be they future patients, the
health system, or society as a whole. Although individual
research subjects may in some cases experience direct
benefits from study participation, they are in all cases
put at risk to benefit others. Informed consent is a key
part of the answer to this question. By providing
informed consent to study participation, research sub-
jects adopt the ends of the study as ends of their own.
In obtaining informed consent, the researcher fulfills the
duty to treat research subjects as persons and not
objects, and as ends in themselves and not mere means
to an end. In short, the function of informed consent is
to allow prospective research subjects to adopt the ends
of the study as their own, thereby (partially) justifying
exposing subjects to risk for the benefit of others.
National and international research ethics guidelines
lay out criteria for informed consent for research parti-
cipation [12-15]. Disclosure requirements generally
include the following elements: an explanation of the
purpose of the study; a description of the study inter-
ventions; a description of the risks and potential benefits
to subjects from research participation; a description of
alternatives available to potential subjects should they
choose not to participate; a description of confidentiality
protections; a statement assuring potential subjects that
participation is voluntary, that they may withdraw at
any time, and that their quality of care will not be
affected should they choose not to participate or to
withdraw; and, information on whom they may contact
with questions. As discussed in detail below, a number
of these guidelines allow for a waiver of consent
[12,13,15]. Accordingly, when a research ethics commit-
tee concludes that it is not feasible to obtain consent
and study participation poses only minimal risk, it may
approve a consent procedure which does not include, or
which alters, some or all of these requirements, or it
may waive the requirement to obtain consent.
Addressing informed consent challenges in CRTs
In an individually randomized clinical trial (RCT), the
human research subject is usually simultaneously the
unit of randomization, the unit of experimentation, and
the unit of observation [1]. Commonly, a patient is allo-
cated randomly to receive one of two or more differing
treatment regimens and data documenting the patient’s
response to the treatment are recorded. As a result,
informed consent in RCTs tends to be straightforward.
Informed consent is obtained from prospective research
subjects prior to randomization and includes consent
for random assignment, study interventions, and data
collection.
Edwards and colleagues, Donner and Klar, and Hutton
have observed that aspects of CRT design, including
cluster randomization, cluster level interventions, and
cluster size, present challenges to obtaining informed
consent [2,3,16]. Clusters may be randomized before
individual cluster members can be identified or
approached. As a result, it is commonly not possible to
obtain informed consent for randomization in CRTs.
Cluster level interventions may be difficult for individual
cluster members to avoid and, as a result, the refusal of
informed consent may be meaningless. Further, when
clusters are large it may not be feasible to obtain
informed consent from all cluster members. Finally, the
units of randomization, experimentation, and observa-
tion may differ so that one group may receive the
experimental intervention while data are collected from
a second group. This means that informed consent for
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random assignment, study interventions, and data col-
lection may have to be obtained separately.
In what follows, we address key questions relating to
informed consent and CRTs using the moral foundation
outlined above and relevant national and international
regulatory provisions.
1. How can a study proceed if informed consent is not
possible?
As explained above, when a CRT involves a cluster level
intervention or large cluster sizes, it may not be possible
to obtain informed consent from study participants. A
CRT reported by Rowland and colleagues illustrates well
the practical difficulties in obtaining informed consent
in certain cases [17].
Falciparum and vivax malaria are important health
problems in Pakistan and indoor spraying of insecticide
is the major preventive method used. The CRT sought
to test the effectiveness of a new insecticide – alphacy-
permethrin – in controlling malaria rates in rural Paki-
stan [17]. The primary outcome measures were the
annual incidence rates of falciparum and vivax malaria.
The 180 km2 study area in Punjab province was divided
into nine sectors and each was randomized to spraying
with one of two preparations of the insecticide or a no
spraying control. In the two intervention arms of the
study, all living quarters, storage rooms, and animal
quarters were sprayed once with the insecticide. Survey
teams visited 400 houses in each district every two
weeks to identify new cases of malaria by symptom
report and, when indicated, a blood smear to look
microscopically for the parasite. Additionally, a cross-
sectional survey collected blood smears from 200 to 300
school children in each sector before and after the inter-
vention period. Village elders were informed of the
study and gave their permission for the study to be con-
ducted. The study concluded that the new insecticide
reduced the annual incidence of falciparum malaria by
95% and vivax malaria by 80%.
In this CRT, all residents within the study area were
deliberately intervened upon via manipulation of their
environment and, hence, are human research subjects.
However, it would have been impossible to obtain the
informed consent of all research subjects in this study.
As the study involved spraying all living quarters, sto-
rage rooms, and animal quarters within a geographic
area, it would have been difficult for cluster members to
avoid the intervention. Even if one refused to allow
one’s own home to be sprayed, one could not practically
avoid all the treated buildings in the community (the
insecticide proved to have an effective half-life of about
six months). As a result, the refusal of informed consent
in this study would have been meaningless. Second,
requiring investigators to obtain the informed consent
of research subjects would have rendered the study
infeasible. Each of the nine study sectors contained
approximately 2000 people living in 400 homes.
The practical impossibility of obtaining informed con-
sent in such cases presents a serious ethical challenge to
CRTs. Above we concluded that the function of
informed consent is to allow prospective research sub-
jects to adopt the ends of the study as their own,
thereby (partially) justifying exposing subjects to risk for
the benefit of others. Thus, informed consent plays a
key role in the ethical justification of human subjects
research. In the absence of some further justification, it
seems that when informed consent cannot be obtained,
a study cannot ethically proceed. Clearly, this conclusion
has undesirable consequences; it would dramatically
restrict the ability to conduct CRTs involving cluster
level interventions or large clusters.
A partial solution is offered by provisions for a waiver
of consent found in a number of national and interna-
tional research ethics guidelines [12,13,15,18]. For
instance, the Council of International Organizations of
Medical Science International Ethical Guidelines for
Biomedical Research Involving Human Subjects – a
widely acknowledged commentary on the Declaration of
Helsinki – contains the following provision:
“when the research design involves no more than
minimal risk and a requirement of individual
informed consent would make the conduct of the
research impracticable (for example, where the
research involves only excerpting data from subjects’
records), the ethical review committee may waive
some or all of the elements of informed consent”
[15].
In short, a research ethics committee may grant a
waiver of consent when it is not feasible to obtain con-
sent and study participation poses only minimal risk.
Limiting the use of a waiver of consent to minimal risk
research is critical to its moral justification. Since
informed consent is key to justifying exposing research
subjects to risk for the benefit of others, waiving the
informed consent requirement can only be contem-
plated in cases in which the risk involved is insignificant.
When a study poses more than minimal risk, the lack of
informed consent would amount to using research sub-
jects as mere means to an end. Thus, when informed
consent cannot be obtained and study procedures
expose subjects to more than minimal risk, we believe a
study cannot proceed ethically.
To illustrate how waiver of consent regulations may
be applied in practice to CRTs, we examine the relevant
provisions in the Common Rule, which governs all
human subjects research supported or conducted by
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federal departments in the United States [12]. The Com-
mon Rule permits a research ethics committee to
“approve a consent procedure which does not include,
or which alters, some or all of the elements of informed
consent set forth in this section, or waive the require-
ments to obtain informed consent provided the
[research ethics committee] finds and documents that:
(a) The research involves no more than minimal risk
to the subjects;
(b) The waiver or alteration will not adversely affect
the rights and welfare of the subjects;
(c) The research could not practicably be carried out
without the waiver or alteration; and,
(d) Whenever appropriate, the subjects will be pro-
vided with additional pertinent information after
participation” [19].
Here we discuss each of these requirements.
(a) The research involves no more than minimal risk to the
subjects
Minimal risk means that “the probability and magnitude
of harm or discomfort anticipated in the research are
not greater in and of themselves than those ordinarily
encountered in daily life or during the performance of
routine physical or psychological examinations or tests”
[20]. In short, study interventions that pose minimal
risk are commensurate with the risks of daily life. The
risks of daily life are those that most or all of us – often
unthinkingly – assume in the course of our daily lives
[21]. These risks include a walk to the store for food
and a routine visit to one’s physician. In the context of
research, routine healthcare, public health, or educa-
tional practice may be considered to involve only mini-
mal risk. Also, certain methods of data collection,
including interviews, surveys, medical records review,
and physical examination, are commonly regarded as
posing minimal risk [22].
Study interventions and data collection procedures in
many CRTs in health research would fulfill the minimal
risk criterion. Commonly, the study interventions evalu-
ated are variations on routine care that do not pose
additional risk to research subjects. Data collection com-
monly involves routinely collected medical information.
Consider the malaria study described above [17]. In it,
the study intervention involved the indoor spraying of
one of two different preparations of an insecticide to
control malaria. In Pakistan, the indoor spraying of
insecticide is the primary approach for malaria preven-
tion. The insecticide used in the study had undergone
prior testing for safety and efficacy and was recom-
mended for use by the World Health Organization [17].
Thus, the study intervention is consistent with standard
public health practice in Pakistan; it poses no more risk
than standard care and may be considered minimal risk.
(The ethical analysis of benefits and harms in CRTs is
the subject of another paper in this series.)
(b) The waiver or alteration will not adversely affect the
rights and welfare of the subjects
This requirement is most helpfully viewed as comple-
menting the requirement that the research involve no
more than minimal risk. It requires that the use of the
waiver of informed consent not violate any legal statute
(U.S. states, for example California, may have specific
informed consent requirements for research enshrined
in legislation). Further, the research ethics committee
must ensure that the welfare interests, including health
interests, financial interests, and legal interests are not
adversely affected by the waiver of consent. The fact
that study participation poses only minimal risk provides
a basis for the belief that the welfare interests of
research subjects are sufficiently protected.
(c) The research could not practicably be carried out
without the waiver or alteration
In CRTs in health research, there are broadly two cir-
cumstances in which a researcher might apply to a
research ethics committee for a waiver of informed con-
sent. In the first case, when a CRT involves a cluster
level intervention or large cluster sizes, it may not be
possible to obtain informed consent from study partici-
pants. In the second case, there may be concern that
information disclosed during the consent process may
substantially bias study outcomes or lead to selection
bias. We discuss each case in turn.
In the first case, a waiver of informed consent may be
sought because a refusal of consent would be meaning-
less or it is not feasible to obtain informed consent from
all cluster members. No rule defines precisely in which
circumstances “research could not practicably be carried
out”. Rather, this determination is within the discretion
of the research ethics committee. The committee may
consider a number of factors in making its judgment,
including the size of the study group, the logistics of
obtaining informed consent, and the financial cost
involved [23]. It falls on the researcher to present a con-
vincing case that these factors apply to a sufficient
degree to the study under consideration to justify the
waiver of consent.
The malaria study would likely satisfy the criterion
that the study could not practicably be carried out with-
out the waiver [17]. As we explained above, the study
intervention could not reasonably be avoided by cluster
members. With an average cluster size of about 2000
people in 400 homes, obtaining informed consent from
all residents in each cluster would be difficult logisti-
cally. Therefore, a research ethics committee could rea-
sonably conclude that the research could not be carried
out without the waiver of consent.
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It is important to note that a waiver of consent may
apply to some, but not all, interventions in a CRT. This
is most likely to occur in CRTs that involve both cluster
level and individual level interventions [4]. Here again
the malaria study is instructive. While the study inter-
vention likely satisfies the requirements for a waiver of
consent, interventions (in the broader sense of the term)
for data collection in the study may not. Malaria annual
incidence was ascertained by screening residents and
obtaining blood samples of individuals with fevers and
from a cross-section of school children [17]. It is gener-
ally feasible – and therefore necessary – to obtain
informed consent for data collection procedures that
involve interaction with research subjects, even if the
procedures themselves pose only minimal risk. Thus, a
waiver of consent would only apply to the spraying of
insecticide in study communities, and researchers
should have obtained informed consent for screening
subjects and taking blood for peripheral smears.
Data collection procedures may be covered by a
waiver of consent if it can be shown that the research
would not be feasible without the waiver. Health ser-
vices and knowledge translation CRTs commonly inter-
vene on health professionals and measure patient
outcomes. As we saw with the Guidelines Trial (dis-
cussed above), if the researcher does not obtain identifi-
able private information (or otherwise intervene upon or
interact with patients), the patients are not research sub-
jects and their informed consent is not required. How-
ever, if the study does involve the collection of
identifiable private information, the researcher may
apply for a waiver of consent for the patients in the
study on the grounds that the research could not prac-
ticably be carried out otherwise [24].
In the second case, a waiver of consent application
may be based on concern that information disclosed
during the consent process may bias study outcomes or
lead to selection bias [2,16,25,26]. CRTs commonly eval-
uate interventions aimed at modifying the behavior of
cluster members. Knowledge of the nature of interven-
tions in other arms of the trial, including the control
arm, may at times plausibly be thought to change peo-
ple’s behaviors and consequently bias the outcome of
the study (i.e., response bias). For example, consider a
CRT evaluating an intervention to improve physician
uptake of clinical practice guidelines. If physicians in the
control group are informed of the details of the study
intervention, they may change their behavior in accord
with the practice guidelines, thus biasing the estimate of
the intervention effect towards the null hypothesis [26].
In the worst case scenario, the study may conclude that
an effective intervention is ineffective; on the other
hand, if the bias is modest, the observed effect may still
be of clinical interest and hence, influence policy.
Separate from response bias, selection bias can be
introduced in a CRT when patients are required to pro-
vide informed consent for data collection after randomi-
zation of their health professionals [27]. Selection bias
does not arise when all patients – or a random subsam-
ple in each arm of the study – consent; however, when
there are different propensities to consent in the inter-
vention and control arms of the study (e.g., when
knowledge of, or exposure to, the experimental or con-
trol interventions influences the likelihood that patients
consent to data collection) this can lead to imbalances
between the trial arms which can bias the estimate of
the intervention effect in an unknown direction and
make the trial results uninterpretable. It has been
argued that modifying or waiving informed consent
requirements in these cases is justified on the grounds
that it is unethical to undertake an experiment that is
scientifically invalid [25].
Researchers can sometimes avoid or mitigate the risk
of selection bias through careful planning of study pro-
cedures and execution [27]. For example, identification
and recruitment can be completed before randomization
if possible, or done by someone blind to the randomiza-
tion status of the group. When such steps are inade-
quate, researchers may apply for a waiver of consent.
There is no specific regulatory guidance defining when
concerns for study validity might outweigh obligations
to obtain informed consent. Generally, we believe that
research ethics committees ought to adopt a restrictive
stance on granting waivers of consent. When applying
for a waiver of consent, investigators should provide evi-
dence that complete disclosure would so bias the study
findings as to make the study practically uninterpretable.
When compelling evidence exists, the research ethics
committee may approve an alteration of the consent
procedures to ensure subjects are blinded to the exact
nature of the interventions. Thus, these cases will
involve an alteration of one or more of the disclosure
requirements, rather than waiving altogether the
requirement to obtain consent. Research ethics commit-
tees should not grant a waiver of consent in the absence
of compelling evidence.
(d) Whenever appropriate, the subjects will be provided
with additional pertinent information
Treating the research subject as a person, not simply as
a means to an end, implies that researchers ought to
make information available about the study whenever
possible. Even when a waiver of consent has been
granted on grounds that obtaining informed consent is
not possible, it may nonetheless be feasible to inform
cluster members of the existence of the study. Informa-
tion may be provided through flyers, letters, or signs in
healthcare institutions that a study is being conducted.
Optionally, these communications may direct interested
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cluster members to a website or a contact person for
further information.
2. Is consent to randomization always required?
In an individually randomized controlled trial, prospec-
tive subjects are approached for informed consent prior
to randomization. In CRTs, however, it may not be possi-
ble to obtain informed consent until after randomization.
Hutton observes that “[s]cientific and logistical con-
straints associated with [CRTs] imply that consent can-
not necessarily be requested before an intervention is
assigned to a person... In some cases it is logically impos-
sible to obtain consent for the intervention prior to ran-
domization of clusters” [16]. Even in CRTs involving an
individual level intervention for which informed consent
will be sought, random assignment of clusters may be
completed before cluster members can be identified or
approached. Some commentators have expressed the
view that the inability to obtain consent for randomiza-
tion may not respect subjects’ autonomy rights [16,28].
The difficulty in obtaining informed consent prior to
randomization is illustrated in a CRT described by Mul-
lany and colleagues [29]. Infection of the umbilical
stump (omphalitis) is an important cause of illness and
death among newborns in developing countries. Mullany
and colleagues conducted a CRT evaluating the effec-
tiveness of an antiseptic – chlorhexidine – in preventing
omphalitis. The study’s primary outcome measures were
infection of the umbilical stump and neonatal mortality.
Clusters of 50-100 households, each served by a local
health worker, were randomized to one of three inter-
ventions for newborns: swabbing the umbilical stump
with chlorhexidine; cleansing it with soap and water;
and dry stump care (the standard care control). From
2002 to 2005, women were approached for informed
consent to study participation in the sixth month of
pregnancy and baseline data on the household were col-
lected. As random allocation of clusters occurred before
the majority of women had become pregnant, it was
impossible to obtain prior consent for randomization.
The health worker visited the household within 24
hours of birth, when possible, and provided umbilical
stump care on days 1, 2, 3, 4, 6, 8, and 10. On each
occasion, any signs of infection were noted; question-
naires regarding neonatal care were completed on days
1 and 14. The study was approved by research ethics
committees in Nepal and the United States. The study
authors concluded that chlorhexidine reduced serious
omphalitis by 75% and reduced the neonatal mortality
risk by 24% compared with dry stump care [29]. There
was no evidence that cleansing the umbilical stump with
soap and water prevented infection.
The ethical principle of respect for persons generally
requires that researchers obtain the informed consent of
research subjects. We have said that the function of
informed consent is to allow prospective research sub-
jects to adopt the ends of the study as their own,
thereby justifying exposing subjects to risk for the bene-
fit of others. This implies that prospective research sub-
jects should be approached for informed consent at the
earliest opportunity and before they are exposed to risk.
In patient RCTs, the earliest opportunity to approach
potential subjects is prior to randomization. However, in
CRTs it may not be possible to obtain individual
informed consent until after randomization. Do CRTs in
which consent to randomization cannot be obtained vio-
late the ethical principle of respect for persons?
It is a dictum in ethics that “ought implies can": ethi-
cal obligations must be possible to fulfill. Given that it
was impossible to approach prospective research sub-
jects before randomization, researchers in this case
approached women for informed consent to study parti-
cipation when they were 6 months pregnant. The ethical
question is whether obtaining the consent of women at
this point achieves the moral purpose of informed con-
sent. We believe it does. Women were approached well
in advance of study or data collection interventions and,
importantly, it is these interventions that place mother
and child at risk (in part) for the benefit of others. They
were informed of the purpose of the study, the interven-
tions they would receive if they agreed to participate,
and alternatives to study participation. Accordingly, the
women approached for informed consent were free to
adopt the ends of the study as ends of their own and to
agree to participate in the study. Women who declined
study participation avoided all study and data collection
interventions and, thus, they were not exposed to risk
for the benefit of others. We conclude that these con-
sent procedures were sufficient to fulfill the moral pur-
pose of informed consent.
As a general rule, prospective research subjects should
be approached for informed consent at the earliest
opportunity. In many CRTs, it is not possible to obtain
informed consent prior to randomization of clusters. So
long as prospective research subjects are approached for
informed consent at the earliest opportunity, and prior
to study or data collection interventions, we believe the
ethical principle of respect for persons is satisfied.
Although consent for randomization is not obtained,
research subjects are nonetheless given the opportunity
to adopt the ends of the study as their own before being
exposed to risk for the benefit of others.
3. What information must be disclosed to potential
subjects if their cluster has already been randomized?
Valid informed consent requires that prospective
research subjects be given sufficient information to
allow them to make a responsible decision regarding
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study participation [11]. As described above, national
and international research ethics guidelines set out
detailed requirements for informed consent [12-15,18].
The information that must be disclosed includes an
explanation of the purpose of the study and a descrip-
tion of the study interventions. When informed consent
takes place prior to randomization, prospective subjects
are provided with detailed information on the study and
data collection procedures in each of the trial’s arms. Of
course, at that time it is unknown to which of the trial’s
arms the subject will be allocated and, as a result, a
responsible decision will require a detailed description
of each of the possible future scenarios.
In the previous section, we discussed the ethical per-
missibility of approaching cluster members for informed
consent after clusters have been randomized in a CRT.
We concluded that if prospective research subjects are
approached for informed consent at the earliest oppor-
tunity, and prior to study or data collection interven-
tions, the moral purpose of informed consent is fulfilled.
Here we ask what information must be disclosed to
potential subjects if their cluster has already been rando-
mized to a particular treatment arm? In these cases,
must subjects receive a detailed description of study and
data collection procedures in each of the CRT’s arms?
When cluster members are approached for consent
after clusters have been randomized, the informed con-
sent process ought to be tailored to the study arm to
which the cluster has been allocated. If prospective
research subjects are to adopt the ends of the study as
their own, the purpose of the study must be described
in sufficient detail to allow them to decide whether the
study’s ends are consonant with their own values and
priorities. Precisely what constitutes “sufficient detail” is
a matter of judgment for the researcher and research
ethics committee. At a minimum, a high-level descrip-
tion of the research question is required; we leave it
open whether this description ought to name the other
interventions compared in the study. Further, prospec-
tive subjects should be informed that their cluster has
already been allocated to one of the study arms. To
make a responsible decision regarding study participa-
tion, prospective subjects also need a clear understand-
ing of the consequences of agreeing to or declining
study participation. This means they must receive a
detailed explanation of the study and data collection
procedures in the trial arm to which their cluster has
been allocated. But when the cluster has already been
randomized to a particular study arm, the possible
future scenarios entailed by other study arms have been
foreclosed. Thus, while the study interventions may be
named in the description of the study’s purpose, a
detailed discussion of the study and data collection pro-
cedures in other trial arms is not required. It is
important to recognize that “tailored consent” is not a
waiver of consent; rather, it is full disclosure in these cir-
cumstances as defined by the moral purpose of
informed consent.
In the Nepal birth study, the informed consent docu-
ment should have been tailored to the trial arm to
which a particular cluster was allocated [29]. For exam-
ple, the consent form provided to pregnant women
whose cluster was assigned to the chlorhexidine arm
should clearly describe the CRT’s purpose. At a mini-
mum, a high-level description of the research question
is required, viz., “Infection of the stump of the umbilical
cord is an important health concern for newborn babies.
The purpose of this study is to determine the best
means of cleaning the umbilical stump to reduce the
risk of infection.” Alternatively, a more detailed descrip-
tion of the CRT’s purpose may be provided: “Infection
of the stump of the umbilical cord is an important
health concern for newborn babies. The purpose of this
study is to determine whether cleansing the umbilical
stump with a mild disinfectant, washing it with soap
and water, or leaving it dry is the best means to reduce
the risk of infection.” The form should then explain that
the cluster to which the woman belongs has already
been allocated to one of the study arms, viz., “The
health worker who will visit you and your baby has
already been assigned to clean the umbilical stumps of
babies with a mild disinfectant solution called chlorhexi-
dine.” The form should describe the chlorhexidine treat-
ments and data collection procedures in detail. A
detailed description of study procedures in other trial
arms need not be provided.
One fortuitous effect of the use of a tailored informed
consent in these circumstances is that the potential for
bias may be mitigated. As we discussed above, commen-
tators have expressed concern that information disclosed
during the consent process may bias study outcomes
[2,16,25,26]. While a clear description of the purpose of
the CRT must be provided in all cases, when informed
consent is tailored to the cluster’s assignment, detailed
information on study procedures in other trial arms
need not be provided. This may reduce the chance that
detailed information on study procedures in other trial
arms will change the behavior of the research subject. It
should be noted, however, that concerns about selection
bias are not affected by this proposal.
4. Is passive consent a valid substitute for informed
consent?
In CRTs of cluster level interventions some researchers
have used so-called “passive consent” to recruit research
subjects. In passive consent, information about the CRT
is provided to prospective research subjects or their sur-
rogate decision makers [26,30-32]. If the prospective
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subject does not object to being enrolled in the CRT,
then the subject is presumed to have agreed to partici-
pate. Here we ask whether passive consent is an accep-
table approach to obtaining the informed consent of
research subjects.
Passive consent is sometimes used in CRTs in educa-
tion and involves sending information about the study
home with students. If a student does not return a
document signed by a parent declining study participa-
tion, the parent is presumed to have consented on
behalf of the student [32]. The information sent home
with the student often contains sufficient information
about the study to enable parents to make an informed
decision regarding study participation [32]. Nonetheless,
there are several shortcomings to passive consent in this
setting. The researcher cannot know whether children
actually provided the study information to their parents.
Further, even if the information is provided to a parent,
there is no assurance that the parent is capable of
understanding the information provided [32]. Thus, the
absence of a written refusal of study participation may
equally reflect valid informed consent, invalid consent
based on misunderstanding, or lack of consent because
the parent never received the information.
In health services research, passive consent is used
somewhat differently. In CRTs conducted in healthcare
settings, notices may be posted in patient areas that
research is being conducted, although detailed informa-
tion about the study is usually not provided. The notices
indicate that if the patient does not wish to participate
in the study, then the patient may contact the investiga-
tor to opt out [26,31,32]. While notices may serve to
increase awareness about the research, passive consent
in this setting also has shortcomings. Typically, notices
do not provide sufficient information to allow for an
informed decision. Further, the absence of contact from
a patient regarding the study may equally reflect a desire
to participate in the study, or a failure to see the notice.
As discussed above, the function of informed consent
is to allow prospective research subjects to adopt the
ends of the study as their own, thereby justifying expos-
ing subjects to risk for the benefit of others. Given the
shortcomings of passive consent, it is difficult to see
how it can reasonably fulfill the moral function of
informed consent. Passive consent is better conceived of
as an alteration of consent; as such, it is subject to the
same regulatory demands as a waiver of consent
[12,13,15,18]. The researcher who wishes to use passive
consent must convince the research ethics committee
that the study is not feasible without the alteration of
consent and study participation poses only minimal risk.
Passive consent is not any more protective of research
subjects’ autonomy rights than a waiver of consent. Its
use may, however, be justified on pragmatic grounds.
For example, in school-based CRTs, passive consent
may be required by school administrators or parent
groups [30]. Other considerations may prompt the use
of passive consent in health care settings. For instance, a
hospital-based CRT evaluating a quality improvement
intervention for diabetes care used passive consent
because “clinicians and the laboratories owned by com-
munity hospitals were worried about public concern as
patients discovered they were enrolled without consent
into a research project” [30].
5. Do health professionals have a moral obligation to
participate as subjects in CRTs designed to improve
professional practice?
Knowledge translation studies commonly intervene on
physicians and other health care professionals to change
practice. For instance, in the Guidelines Trial (discussed
above), birth attendants in hospitals randomized to the
intervention arm were trained in guidelines for the use
of episiotomy and the management of the third stage of
labor and received reminders regarding key practices
[8]. Since the birth attendants were the direct recipients
of the study intervention, they were human research
subjects. Researchers have a general obligation to obtain
the informed consent of research subjects. In the Guide-
lines Trial, researchers obtained the informed consent of
all birth attendants in the study. However, in cases in
which the intervention is administered to groups of
health care providers or if their numbers are large, it
may not always be possible to obtain informed consent.
In these circumstances, researchers may apply to the
research ethics committee for a waiver of consent.
Some have argued that health care professionals have
an obligation to participate in health systems or knowl-
edge translation CRTs [16,25]. Hutton argues that “[i]n
some cases, the experimental units, professionals, might
have a duty to enroll as part of their continuing profes-
sional development” [16]. In a subsequent article, Hut-
ton and colleagues make the following further claim: “[I]
f a health care professional chooses not to participate in
a study, they are in effect denying their patients the
potential benefits of participation. Health care providers
ought to do the best for their patients...” [25]. Here we
ask whether continuing professional development or the
prospect of benefit for patients ground an obligation for
health professional to participate as research subjects in
CRTs. If they do, does this imply that the informed con-
sent of health professionals is not required?
Health care professionals are required to engage in
continuing professional development as a condition of
licensure in many jurisdictions [33]. Physicians are
afforded a great deal of latitude in determining the
means by which continuing education is obtained.
Acceptable options may include self study, conference
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attendance, teaching preparation, and participation in
educational programs leading to a diploma or degree
[34]. The wide discretion in choosing professional devel-
opment activities undermines the claim that health pro-
fessionals have an obligation to participate as subjects in
a CRT. The simple fact is that health care professionals
may achieve the end of improving their skills and
knowledge through other – equally legitimate – means.
Regarding the second argument, it is true that
knowledge translation and quality improvement studies
seek to improve patient care. But the fact that an edu-
cational or quality improvement intervention is being
evaluated in a CRT suggests that its effectiveness is
unproven. Indeed, if it was known at the start of the
trial that the study intervention is effective, the CRT
would be unethical [35]. Additionally, the claim that
the health care professional has an obligation to parti-
cipate in research seems difficult to square with the
fact that such CRTs will include a usual care or no
intervention control group. If denying patients access
to the benefit of the study intervention is morally
questionable, then how is the control arm ethically jus-
tified? (The applicability of clinical equipoise to ques-
tions such as these in CRTs is explored in another
paper in the series [36]). Thus, the prospect of denying
patients potential benefits does not seem to ground an
obligation for participation.
A more fruitful line of reasoning starts with the
recognition that health research is a socially important
activity. Such research is critical to ensure that treat-
ments are safe and effective, and that new treatments
for disease continue to be developed. Health services
and knowledge translation research help ensure that
when advances are made, they are actually implemen-
ted in medical practice in sustainable and affordable
ways. It has been argued that the social importance of
health research grounds a general obligation to support
and even participate in research [37]. This may be
thought to apply equally to patients and health care
professionals. Thus, as Hutton and colleagues put it,
“[t]his might suggest that [health care professionals]
should have a high threshold for opting out of imple-
mentation research studies” [25]. In other words,
health professionals ought to have a good reason to
decline participation as subjects in a CRT. It is impor-
tant to recognize that our position falls well short of
concluding that a health professional has an enforce-
able obligation to participate in a specific trial (as one
could always participate legitimately in another study)
[37]. Finally, recognizing this general obligation does
not diminish – in any way– the need to obtain the
informed consent of health care professionals [37].
Conclusion
This paper addresses the question: from whom, when,
and how must informed consent be obtained in CRTs
in health research? The ethical principle of respect for
persons implies that researchers are generally obligated
to obtain the informed consent of research subjects.
Aspects of CRT design, including cluster randomization,
cluster level interventions, and cluster size, present chal-
lenges to obtaining informed consent. Here we address
five questions related to consent and CRTs: How can a
study proceed if informed consent is not possible? Is
consent to randomization always required? What infor-
mation must be disclosed to potential subjects if their
cluster has already been randomized? Is passive consent
a valid substitute for informed consent? Do health pro-
fessionals have a moral obligation to participate as sub-
jects in CRTs designed to improve professional practice?
We set out a framework based on the moral founda-
tions of informed consent and international regulatory
provisions to address each of these questions. First,
when informed consent is not possible, a study may
proceed if a research ethics committee is satisfied that
conditions for a waiver of consent are satisfied. Second,
informed consent to randomization may not be required
if it is not possible to approach subjects at the time of
randomization. Third, when potential subjects are
approached after cluster randomization, they must be
provided with a detailed description of the interventions
in the trial arm to which their cluster has been rando-
mized; detailed information on interventions in other
trial arms need not be provided. Fourth, while passive
consent may serve a variety of practical ends, it is not a
substitute for valid informed consent. Fifth, while health
professionals may indeed have a moral obligation to par-
ticipate as subjects in research, this does not diminish
the necessity of informed consent to study participation.
Note
We have created a Wiki webpage to facilitate an open
discussion about the ideas expressed in this and other
papers published in the series on ethical challenges in
CRTs. Please enter your thoughts and comments at
http://crtethics.wikispaces.com.
Acknowledgements
This study has been funded by operating grants from the Canadian
Institutes of Health Research. The funding agency had no role in the study
design, collection, analysis or interpretation of data, writing of the
manuscript or in the decision to submit the manuscript for publication. AB’s
research is funded by a Frederick Banting and Charles Best Canada Graduate
Scholarships Doctoral Award from the Canadian Institutes of Health
Research. ADM was supported by a Fellowship Award from the Canadian
Institutes of Health Research. JMG and CW both hold Canada Research
Chairs.
McRae et al. Trials 2011, 12:202
http://www.trialsjournal.com/content/12/1/202
Page 11 of 13
Author details
1Department of Epidemiology and Biostatistics, University of Western
Ontario, London, ON, N6A 5C1, Canada. 2Division of Emergency Medicine,
University of Calgary, Foothills Medical Centre, 1403 29th Street NW, Calgary,
AB, T2N 2T9, Canada. 3Rotman Institute of Philosophy, Department of
Philosophy, University of Western Ontario, London, ON, N6A 5B8, Canada.
4Department of Medicine, University of Western Ontario, 339 Windermere
Road, London, ON, N6A 5A5, Canada. 5Ottawa Hospital Research Institute,
Clinical Epidemiology Program, Civic Campus, 1053 Carling Avenue, Ottawa,
ON, K1Y 4E9, Canada. 6Department of Medicine, Faculty of Medicine,
University of Ottawa, Ottawa, ON, K1H 8L6, Canada. 7Graduate School of
Education and Statistics Department, Wharton School, University of
Pennsylvania, 3700 Walnut Street, Philadelphia, PA, 19104, USA. 8Department
of Epidemiology and Community Medicine, University of Ottawa, Ottawa,
ON, K1H 8M5, Canada. 9Robarts Clinical Trials, Robarts Research Institute,
London, ON, N6A 5K8, Canada. 10Institute of Health and Society, Newcastle
University, Baddiley-Clark Building, Richardson Road, Newcastle upon Tyne,
NE2 4AX, UK. 11Department of Medicine, University of Ottawa and Ottawa
Hospital, Ottawa Hospital Research Institute, 1053 Carling Avenue, Ottawa,
ON, K1Y 4E9, Canada.
Authors’ contributions
ADM, CW, AB, MT and JMG contributed to the conception and design of
the manuscript.
ADM wrote the initial draft, and ADM and CW led writing of subsequent
versions.
All authors commented on sequential drafts and approved the final version.
Competing interests
AB, JCB, ADM, RS, MT, CW, and AW: None declared
RB, AD, MPE, and JMG have all submitted cluster trial protocols to ethics
committees and had difficulty explaining to them the differences between
cluster randomized trials and individual patient clinical trials.
Received: 12 June 2011 Accepted: 9 September 2011
Published: 9 September 2011
References
1. Weijer C, Grimshaw JM, Taljaard M, Binik A, Boruch R, Brehaut JC, Donner A,
Eccles MP, Gallo A, McRae AD, Saginur R, Zwarenstein M: Ethical issues
posed by cluster randomized trials in health research. Trials 2011, 12:100.
2. Edwards SJ, Braunholtz DA, Lilford RJ, Stevens AJ: Ethical issues in the
design and conduct of cluster randomised controlled trials. BMJ 1999,
318(7195):1407-9.
3. Donner A, Klar N: Design and Analysis of Cluster Randomization Trials in
Health Research London: Arnold; 2000.
4. U.K. Medical Research Council: Cluster Randomized Trials: Methodological and
Ethical Considerations London UK; 2002 [http://www.mrc.ac.uk/
consumption/idcplg?
IdcService=GET_FILE&dID=8241&dDocName=MRC002406&allowInterrupt=1],
date accessed: July 24, 2011.
5. Eldridge SM, Ashby D, Feder GS: Informed patient consent to
participation in cluster randomized trials: an empirical exploration of
trials in primary care. Clin Trials 2005, 2(2):91-8.
6. McRae AD: Factors associated with reporting of patient consent in
healthcare cluster randomized trials. Ethical Challenges in Cluster
Randomized Trials. PhD Thesis University of Western Ontario, Department of
Epidemiology and Biostatistics; 2011, London ON.
7. McRae AD, Weijer C, Binik A, White A, Grimshaw JM, Baruch R, Brehaut JC,
Donner A, Eccles M, Saginur R, Taljaard MM: Who is the research subject
in cluster randomized trials in health research? Trials 2011, 12:183.
8. Althabe F, Buekens P, Bergel E, Belizán JM, Campbell MK, Moss N,
Hartwell T, Wright LL, Guidelines Trial Group: A behavioral intervention to
improve obstetrical care. N Engl J Med 2008, 358:(18):1929-40.
9. Faden RR, Beauchamp TL, King NMP: A History and Theory of Informed
Consent New York: Oxford University Press; 1986.
10. Veatch RM: Three theories of informed consent: philosophical
foundations and policy implications. In The Belmont Report. Appendix
(Volume 2). Volume 26. Washington: US Government Printing Office;
1979:1-66.
11. Freedman B: A moral theory of informed consent. Hastings Cent Rep 1975,
5:(4):32-9.
12. Department of Health and Human Services: Protection of Human Subjects
Washington USA; 2005 [http://ohsr.od.nih.gov/guidelines/45cfr46.html], date
accessed July 24, 2011.
13. Canadian Institutes of Health Research, Natural Sciences and Engineering
Research Council, Social Sciences and Humanities Research Council: Tri-
Council Policy Statement: Ethical Conduct of Research Involving Humans
Ottawa Canada; 2010 [http://www.pre.ethics.gc.ca/pdf/eng/tcps2/
TCPS_2_FINAL_Web.pdf], date accessed: July 24, 2011.
14. World Medical Association: Declaration of Helsinki: Ethical Principles for
Medical Research Involving Human Subjects Ferney-Voltaire France; 2008
[http://www.wma.net/en/30publications/10policies/b3/index.html], date
accessed: July 24, 2011.
15. Council of International Organizations of Medical Science: International
Ethical Guidelines for Biomedical Research Involving Human Subjects Geneva
Switzerland; 2002 [http://www.cioms.ch/publications/layout_guide2002.pdf],
date accessed: July 24, 2011.
16. Hutton JL: Are distinctive ethical principles required for cluster
randomized controlled trials? Stat Med 2001, 20(3):473-88.
17. Rowland M, Mahmood P, Iqbal J, Carneiro A, Chavasse D: Indoor residual
spraying with alphacypermethrin controls malaria in Pakistan: a
community-randomized trial. Trop Med Int Health 2000, 5(7):472-81.
18. National Health and Medical Research Council, Australian Research Council,
Australian Vice-Chancellors’ Committee: National Statement on Ethical
Conduct in Human Research Canberra Australia; 2007 [http://www.nhmrc.
gov.au/publications/synopses/e72syn.htm], date accessed: July 24, 2011.
19. Department of Health and Human Services: Protection of Human Subjects.
46.116(d) Washington USA; 2005 [http://ohsr.od.nih.gov/guidelines/45cfr46.
html], date accessed July 24, 2011.
20. Department of Health and Human Services: Protection of Human Subjects.
46.102(i) Washington USA; 2005 [http://ohsr.od.nih.gov/guidelines/45cfr46.
html], date accessed July 24, 2011.
21. Freedman B, Fuks A, Weijer C: In loco parentis: minimal risk as an ethical
threshold for research upon children. Hastings Cent Rep 1993, 23(2):13-9.
22. U.S. Office for Human Research Protections: Categories of Research That May
Be Reviewed by the Institutional Review Board (IRB) through an Expedited
Review Procedure Washington USA; 1998 [http://www.hhs.gov/ohrp/policy/
expedited98.html], date accessed: July 24, 2011.
23. National Bioethics Advisory Commission: Research Involving Human
Biological Materials: Ethical Issues and Policy Guidance: Rockville, MD:
National Bioethics Advisory Commission; 1999.
24. Canadian Institutes of Health Research: Background Legal Research and
Analysis in Support of CIHR’s Recommendations with Respect to the Personal
Information and Protection and Electronic Documents Act (PIPEDA) (S.C. 2000,
c.5) as at November 30, 2001 Ottawa Canada; 2001 [http://www.cihr.ca/e/
documents/legal_analysis_e.pdf], date accessed July 24, 2011.
25. Hutton JL, Eccles MP, Grimshaw JM: Ethical issues in implementation
research: a discussion of the problems in achieving informed consent.
Implementation Sci 2008, 3:52.
26. Winkens RA, Knottnerus JA, Kester AD, Grol RP, Pop P: Fitting a routine
health-care activity into a randomized trial: an experiment possible
without informed consent? J Clin Epidemiol 1997, 50(4):435-9.
27. Puffer S, Torgerson D, Watson J: Evidence for risk of bias in cluster
randomised trials: review of recent trials published in three general
medical journals. BMJ 2003, 327(7418):785-9.
28. Donner A, Klar N: Pitfalls of and controversies in cluster randomization
trials. Am J Public Health 2004, 94(3):416-22.
29. Mullany LC, Darmstadt GL, Khatry SK, Katz J, LeClerq SC, Shrestha S,
Adhikari R, Tielsch JM: Topical applications of chlorhexidine to the
umbilical cord for prevention of omphalitis and neonatal mortality in
southern Nepal: a community-based, cluster-randomised trial. Lancet
2006, 367(9514):910-8.
30. Ross JG, Sundberg EC, Flint KH: Informed consent in school health
research: why, how and making it easy. J Sch Health 1999, 69(5):171-6.
31. Littenberg B, Maclean CD: Passive consent for clinical research in the age
of HIPAA. J Gen Int Med 2006, 21(3):207-11.
32. Dziak K, Anderson R, Sevick MA, Weisman CS, Levine DW, Scholle SH:
Variations among institutional review board reviews in a multisite health
services research study. Health Serv Res 2005, 40:(1):279-90.
McRae et al. Trials 2011, 12:202
http://www.trialsjournal.com/content/12/1/202
Page 12 of 13
33. American Medical Association: AMA’s Code of Medical Ethics Chicago USA;
[http://www.ama-assn.org/ama/pub/physician-resources/medical-ethics/
code-medical-ethics.shtml], date accessed July 24, 2011.
34. Royal College of Physicians and Surgeons of Canada: Using the Framework
of Continuing Professional Development Activities Ottawa Canada; 2006
[http://www.rcpsc.edu/opa/moc-program/2006framework_e.pdf], date
accessed July 24, 2011.
35. Freedman B: Equipoise and the ethics of clinical research. N Engl J Med
1987, 317(3):141-5.
36. Binik A, Weijer C, McRae AD, Grimshaw JM, Baruch R, Brehaut JC, Donner A,
Eccles MP, Saginur R, Taljaard M, Zwarenstein M: Does clinical equipoise
apply to cluster randomized trials in health research? Trials 2011, 12:118.
37. Shapshay S, Pimple KD: Participation in biomedical research is an
imperfect moral duty: a response to John Harris. J Med Ethics 2007,
33(7):414-7.
doi:10.1186/1745-6215-12-202
Cite this article as: McRae et al.: When is informed consent required in
cluster randomized trials in health research? Trials 2011 12:202.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
McRae et al. Trials 2011, 12:202
http://www.trialsjournal.com/content/12/1/202
Page 13 of 13
